SCHEMBL19971600

SCHEMBL19971600

O=C(O)c1cc(F)cc(Br)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.44
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43
AKR1C4 P17516 2/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
AKR1C1 Q04828 2/20 0.41
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
HCAR1 Q9BXC0 1/20 0.38
PTPN1 P18031 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30955021 1.00 KEAP1 (0.44) KEAP1CES2CES1AKR1C4AKR1C3
SCHEMBL28141308 0.83 CES2 (0.43) KEAP1CES2CES1PKMGPR17
SCHEMBL5854041 0.83 AKR1C3 (0.61) KEAP1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL31284177 0.83 KEAP1 (0.44) KEAP1CES2CES1AKR1C4AKR1C3
SCHEMBL31457965 0.81 AKR1C4 (0.44) KEAP1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL18000505 0.81 AKR1C4 (0.44) KEAP1AKR1C4AKR1C3AKR1C2AKR1C1
SCHEMBL31284332 0.81 AKR1C2 (0.64) KEAP1CES2CES1AKR1C4AKR1C3
SCHEMBL20944591 0.81 AKR1C2 (0.64) KEAP1CES2CES1AKR1C4AKR1C3
SCHEMBL21932841 0.81 KEAP1 (0.42) KEAP1CES2CES1AKR1C4AKR1C3
SCHEMBL16122465 0.81 TTR (0.54) AKR1C4AKR1C3AKR1C2AKR1C1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112543764-B Amide compound with BET proteolytic induction effect and medical application thereof 田边三菱制药株式会社 2024-05-10 CN disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
CN-112543764-A Amide compound with BET proteolysis induction effect and medical application thereof 田边三菱制药株式会社 2021-03-23 CN disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed
CN-110511209-A It can be used as the indole carboxamides compound of kinase inhibitor BRISTOL MYERS SQUIBB CO 2019-11-29 CN disclosed
WO-2018057219-A1 METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES SPECTRUM TRACER SERVICES, LLC (US) 2018-03-29 WO disclosed
US-20180080314-A1 METHOD OF ALLOCATING INDIVIDUAL OIL OR WATER PRODUCTION CONTRIBUTIONS FROM MULTIPLE COMBINED SOURCES SPECTRUM TRACER SERVICES, LLC 2018-03-22 US disclosed
CN-105358546-B The tetrahydro carbazole being substituted and carbazole carboxamide compounds useful as kinase inhibitor 百时美施贵宝公司 2017-10-31 CN disclosed
CN-107108583-A Indole carboxamide compounds useful as kinase inhibitors 百时美施贵宝公司 2017-08-29 CN disclosed
CN-107108555-A Three ring atropisomer compounds 百时美施贵宝公司 2017-08-29 CN disclosed
CN-107074804-A Carbazole derivates 百时美施贵宝公司 2017-08-18 CN disclosed
CN-106661051-A Antibacterial compounds 莱德克斯制药公共有限公司 2017-05-10 CN disclosed
CN-104395297-B Sulfonamide derivatives and pharmaceutical use thereof AJINOMOTO CO.,INC. (JP) 2016-05-04 CN disclosed
CN-102015674-B Modulators of dopamine neurotransmission NSAB FILIAL AF NEUROSEARCH SWEDEN AB SVERIGE (DK) 2014-10-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB KEAP1 1521/4885CES2 3690/4885CES1 2432/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB KEAP1 1394/4885CES2 3649/4885CES1 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.